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Short inter-pregnancy interval and schizophrenia:
overestimating the risk
The short report by Gunawardana et al1 succinctly argues that a
short inter-pregnancy interval, a proxy for fetal undernutrition
and stress, increases the offspring’s risk of later schizophrenia.
The authors hint at a causal relationship. This is compelling
because it suggests that an affordable public health intervention
via the promotion of dietary supplements in the postpartum
period may later reduce schizophrenia prevalence.
Although the authors compare pre- and post-birth intervals
and adjust for a number of confounders, their findings may still
relate to bias and residual confounding. First, the timing of
schizophrenia measurement may distort the prevalence and
gender ratio of schizophrenia. This is important because a short
inter-pregnancy interval is known to favour male offspring.2
Looking at the cohort’s median year of birth (1978) and the latest
possible date of outcome measurement (2002), an individual’s
lifetime history of schizophrenia would be recorded at 24 years.
As there is a significant gender variation in the age-specific
incidence of schizophrenia,3 the median cohort age of 24 years
is likely to bias the cohort towards male schizophrenia prevalence
and overestimate the predictive validity of the short inter-pregnancy
interval.
Second, the finding of no relationship between the post-birth
inter-pregnancy interval and later schizophrenia does not discount
residual confounders, including ethnicity and genetic factors,
from contributing to the study’s main findings. Genetic and
familial factors, including ethnicity, are both associated with short
inter-pregancy intervals4,5 and schizophrenia.6 The current study
did not mention adjusting for offspring ethnicity, although its
design would make it possible. However, any epidemiological
study would struggle to separate the prenatal effect of the
inter-pregnancy interval from maternal–child genome sharing.
Epidemiological designs will only drive hypotheses so far in
examining the causal relationship between prenatal micronutrient
depletion and later psychopathology. That said, there would be
scientific value in examining cohorts pre- and post-introduction
of public health recommendations of periconceptional folic acid
vitamin supplementation. In addition, further work analysing
the correlates of prenatal nutrient depletion as additive risk factors
could provide further evidence of a dose–response relationship.
For example, are the risks of schizophrenia enhanced when there
is a history of short pre-birth interval plus prior multiple births,
concurrent breastfeeding or postnatal vitaminosis?
Introducing postnatal vitamin supplementation to reduce
schizophrenia prevalence is an enticing idea; however, it would be
important to use a variety of research designs to establish or exclude
causality before implementing any change in public health policy.
1 Gunawardana L, Davey Smith G, Zammit S, Whitley E, Gunnell D, Lewis S,
et al. Pre-conception inter-pregnancy interval and risk of schizophrenia. Br J
Psychiatry 2011; 199: 338–9.
2 Greenberg RA, White C. The sexes of consecutive sibs in human sibships.
Hum Biol 1967; 39: 374–404.
3 Thorup A, Waltoft BL, Pedersen CB, Mortensen PB, Nordentoft M. Young
males have a higher risk of developing schizophrenia: a Danish register
study. Psychol Med 2007; 37: 479–84.
4 Rodgers JL, Kohler HP, Christensen K. Genetic variance in human fertility:
biology, psychology, or both? In The Biodemography of Human Reproduction
and Fertility (eds JL Rodgers, HP Kohler): 229–50. Springer, 2003.
5 Rawlings JS, Rawlings VB, Read JA. Prevalence of low birth weight and
preterm delivery in relation to the interval between pregnancies among
white and black women. N Engl J Med 1995; 332: 69–74.
6 Fearon P, Kirkbride JB, Morgan C, Dazzan P, Morgan K, Lloyd T, et al.
Incidence of schizophrenia and other psychoses in ethnic minority groups:
results from the MRC AESOP Study. Psychol Med 2006. 36(11): 1541–50.
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Authors’ reply: We agree with Downs & Jonas that it is
important to establish whether the association between inter-
pregnancy interval and schizophrenia is indeed causal, and that
residual confounding is a potential explanation for our findings.
Residual confounding is, of course, a potential explanation for
any association in observational epidemiological studies, as we
discuss in our paper.1 However, we believe that one of the
strengths of our study is that we compare the relationship between
the pre-birth inter-pregnancy interval and risk of schizophrenia
with that of the post-birth inter-pregnancy interval and risk of this
disorder. If the association between pre-birth inter-pregnancy
interval and risk of schizophrenia is due to confounding, we
would expect to observe a similar relationship for the post-birth
interval, but we did not find this in our study. Although it is
possible that there are confounders that are associated with pre-
birth, but not post-birth inter-pregnancy intervals, this seems
rather unlikely for most potential confounders.
For example, Downs & Jonas suggest that one such possible
confounder is ethnicity, whereby individuals born to families from
specific ethnic groups may be more likely to be conceived
following a shorter pre-birth inter-pregnancy interval, as well as
to have an increased risk of schizophrenia. However, if this were
true then we would expect to see the same (confounded)
relationship between post-birth inter-pregnancy interval and risk
of schizophrenia. Comparing results for pre-birth and post-birth
intervals allows us to be slightly more confident (although by
no means certain) that unmeasured confounders do not provide
an adequate explanation for our findings, and that the increased
risk of schizophrenia following a shorter pre-birth inter-pregnancy
interval might be causal. What it is about a shorter pre-birth inter-
pregnancy interval that leads to an increased risk of schizophrenia
is, as yet, unknown,1 although arguments that this acts as a proxy
for fetal undernutrition or exposure to stress have received the
greatest support in the literature to date.2-5
Downs & Jonas also argue that short inter-pregnancy intervals
favour male offspring and that, given the gender variation in
age-specific incidence of schizophrenia, this could lead to an
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overestimation of the effect of a shorter inter-pregnancy interval.
However, if male gender was indeed on the causal pathway
between inter-pregnancy interval and schizophrenia, this would
not, of itself, lead to a biased estimate of association between
inter-pregnancy interval and schizophrenia. Furthermore, if male
gender was indeed on the causal pathway, then adjusting for
gender should lead to an attenuation of the association between
inter-pregnancy interval and schizophrenia; however, adjusting
for gender made no difference to our results,1 indicating that
gender is unlikely to be an adequate explanation as a mechanism
for the association with shorter inter-pregnancy interval.
1 Gunawardana L, Davey Smith G, Zammit S, Whitley E, Gunnell D, Lewis S,
et al. Pre-conception inter-pregnancy interval and risk of schizophrenia. Br J
Psychiatry 2011; 199: 338–9.
2 Chabrol H, Chauchard E, Girabet J. Cannabis use and suicidal behaviours in
high-school students. Addict Behav 2008; 33: 152–5.
3 Cheslack-Postava K, Liu K, Bearman PS. Closely spaced pregnancies are
associated with increased odds of autism in California sibling births.
Pediatrics 2011; 127: 246–53.
4 Smits L, Pedersen C, Mortensen P, van Os J. Association between short birth
intervals and schizophrenia in the offspring. Schizophr Res 2004; 70: 49–56.
5 Smits LJ, Essed GG. Short interpregnancy intervals and unfavourable
pregnancy outcome: role of folate depletion. Lancet 2001; 358: 2074–7.
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Care clusters and mental health Payment by Results
In their piece on mental health Payment by Results,1 Macdonald &
Elphick note ‘a lack of reassurance that costs per case within a
cluster will be similar enough to support a viable tariff calculation’.
This may underestimate the difficulties with the proposed new
payment mechanism, which may have effects wider than
disruption of nascent routine outcome measurement systems.
The UK has come relatively late to the process of payment
reform for mental health services, but despite this it has followed
an approach unlike that in other countries. The fundamental
principle behind the care cluster approach seems to be the
presumption that individuals with similar needs for care, as
notionally defined by clusters of scores on the Health of the
Nation Outcome Scales (HoNOS), will receive similar care and
therefore incur similar costs. Importantly, costs themselves did
not enter into the original process of defining care clusters.2
The approach pioneered by Fetter at Yale3 in developing the
original Medicare prospective payment system in the 1980s was
to combine consultation with clinicians and statistical analysis
of clinical, administrative and cost data using variance reduction
so that case-mix groupings are both expected to produce similar
‘clinical responses’ and also do in fact demonstrate acceptable
homogeneity of costs. This approach was also followed by
Australia and New Zealand,4,5 when they attempted to develop
payment systems based on HoNOS. Achieving homogeneous costs
within groups is crucial because it minimises the random risk to
providers (the risk that appropriately incurred costs and therefore
revenue differ randomly from those reimbursed). A typical cut-off
for acceptable cost homogeneity is for each case-mix group to
have a coefficient of variation of one or less (mean divided by
standard deviation). It is also essential to make sure that factors
relevant in resource use which may be more or less prevalent
among different providers are also represented; otherwise there
may be an element of systematic risk, with certain providers being
systematically underpaid and others systematically overpaid. Even
when this more standard approach is followed, it may not be
successful, especially in mental health, where cost variation is high.
Infamously, the original Medicare prospective payment system
was never implemented in specialist mental health units in the face
of evidence that resource homogeneity was too low and that the
system would systematically disadvantage those units, and has
now been abandoned in favour of an across the board per diem
payment system for psychiatric in-patients.6 Neither the
Australian nor New Zealand systems were ever implemented.
In the light of the foregoing comments, it is perhaps not
surprising that the Department of Health’s own pilot studies from
2006 demonstrate both that resource homogeneity of care clusters
is unacceptably low, with only 1 of 13 clusters having a coefficient
of variation of less than one, and also that far better homogeneity
could have been achieved, especially for in-patients, had the
standard variance-reduction approach been followed.7 At present,
it seems to me that the lowest risk approach to reforming payment
for mental health services is to adopt a basic system of activity-
based funding, and use the data collected in this way, along with
clinical and administrative data, as part of a slow and careful
process of reform. Certainly, payment for mental health services
in the UK is ripe for reform, as variations in resource use between
providers are far wider than could be accounted for by any
difference in case-mix.8 But this may not be the best way of
approaching it.
1 Macdonald AJD, Elphick M. Combining routine outcomes measurement and
‘Payment by Results’: will it work and is it worth it? Br J Psychiatry 2011;
199: 178–9.
2 Self R, Rigby A, Leggett C, Paxton R. Clinical Decision Support Tool: a rational
needs-based approach to making clinical decisions. J Ment Health 2008; 17:
33–48.
3 Fetter RB. Health Care Financing Grants and Contracts Report: The New
ICD-9-CM Diagnosis Related Groups Classification Scheme. Health Care
Financing Administration, 1983. Available from: http://babel.hathitrust.org/
cgi/pt?id=mdp.39015009571160.
4 Buckingham B, Burgess P, Solomon S, Pirkis JE, Eagar K. Developing a
Casemix Classification for Mental Health Services. Volume 1: Main Report.
Commonwealth Department of Health and Family Services, 1998.
5 Eagar K, Gaines P, Burgess P, Green J, Bower A, Buckingham B, et al.
Developing a New Zealand casemix classification for mental health services.
World Psychiatry 2004; 3: 172–7.
6 Lave JR. Developing a Medicare prospective payment system for inpatient
psychiatric care. Health Aff 2003; 22: 97–109.
7 Health and Social Care Information Centre Casemix Service. Mental Health
Casemix Classification Development: End Stage Report. Health and Social
Care Information Centre, 2006.
8 Audit Commission. Maximising Resources in Adult Mental Health. Audit
Commission, 2010.
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The key to doing routine mental health outcomes well1 is to make
them relevant, meaningful and available to practitioners, service
users and managers. The Health of the Nation Outcome Scales
(HoNOS) is now a front-runner for a general outcome measure
since it is required for Payment by Results, a new contracting
system for mental healthcare in the UK. Only one HoNOS rating
is currently required in order to allocate patients to Payment by
Results care clusters, so managers have little incentive to take
the extra step and mandate more than one HoNOS rating to assess
the effectiveness of interventions. The simplest way to introduce
outcome measurement with HoNOS would be to mandate at
least two ratings, one at the outset of an intervention and one
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at the close. A benchmark for this approach has been set by
the Priory Group for HoNOS outcomes of in-patient
stays (www.priorygroup.com/Personal-Site/About-Priory/About-
Us/Healthcare-Outcomes/General-Psychiatry.aspx). Psychological
therapists are ahead of the curve, since many already use a
commercial outcomes tool (e.g. Clinical Outcomes in Routine
Evaluation, CORE; www.coreims.co.uk) in their work to monitor
treatment progress, to support reflection and to aid supervision.
They also involve patients, who make their own ratings on a
standard questionnaire. They have made outcomes relevant and
meaningful. Could their experience help develop HoNOS as an
outcome tool? The HoNOS could be put to work supporting
practitioners. For example, HoNOS could inform referral and
assessment systems, by helping select between primary and
secondary care services. If no individual HoNOS item rating is
greater than 2 (mild), then secondary services may not be
indicated. Individual scale scores could also indicate priorities
for interventions: a high score on ‘hallucinations and delusions’
and a low score on ‘living conditions’ could suggest a focus on
treatment over accommodation (and vice versa). The HoNOS total
and individual scale scores would also indicate progress and could
be used in supervision. The HoNOS scores that fall below predeter-
mined thresholds may indicate readiness for discharge. These could
even be agreed as goals with patients. Co-producing HoNOS with
service users and carers could balance the perspective of HoNOS
as a clinician-rated measure. Getting all practitioners on board will
need vision and effort. Gilbody et al2 found that psychiatrists were
not very interested in recording standardised outcomes. Feedback
is crucial to engagement. Trusts should invest time to design their
information systems so that they report person-centred outcomes
directly to practitioners and teams in a meaningful format. Simply
reporting outcome returns centrally would miss a huge opportunity
to engage clinicians with outcomes, but still burden them with data
collection. Outcomes information will create new challenges, for
example the apparent ability to compare the effectiveness of teams
and individual practitioners. For some, this could be intensely
motivating or intimidating. The introduction of standard out-
come measures should be done thoughtfully with ongoing input
from service users, practitioners, managers and academics; or as
Macdonald & Elphick put it: well.
Declaration of interest
Outcomes data affect my appraisal. I have a clinical information
lead role in my trust.
1 Macdonald AJD, Elphick M. Combining routine outcomes measurement and
’Payment by Results’: will it work and is it worth it? Br J Psychiatry 2011;
199: 178–9.
2 Gilbody SM, House AO, Sheldon TA. Psychiatrists in the UK do not use
outcomes measures. National survey. Br J Psychiatry 2002; 180: 101–3.
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doi: 10.1192/bjp.200.2.161a
MacDonald & Elphick1 have lucidly described the proposed
introduction of Payment by Results into mental health. They
mention, however, that ‘concerns include the validity and reliabil-
ity of the MHCT’ (mental health clustering tool), and there is also
the major issue of how cost can be firmly linked to the quality of
services delivered.
The Department of Health approach to reliability has been to
rely on local initiatives and to commission the development of an
algorithm based on the MHCT to ensure that clusters are reliably
allocated. Exactly why the Department of Health believes that this
is possible by either route is not clear. Local initiatives are the
route to mayhem and none of the attempts at devising algorithms
so far have been successful. The instrument on which the MHCT
is based, Health of the Nation Outcome Scales (HoNOS), was not
devised for this purpose. Additional items have been added but
this was for clinical reasons. The HoNOS was devised as a clinical
outcome measure, not for needs assessment and certainly not as a
classification tool. Internationally recognised tools (e.g. Schedules
for Clinical Assessment in Neuropsychiatry, Structured Clinical
Interview for DSM Disorders) have been devised to classify
conditions but these use a range of information (e.g. symptoms,
beliefs and timescales), with specified criteria that have been and
continue to be subject to international expert scrutiny.
A unit of costing must be directly related to quality and
outcome measures or the UK will have the same problems as
the USA have encountered in its payment systems. It is difficult
to understand how clusters can be such units of cost unless there
is a very substantial body of research investigating evidence for
efficacy of interventions (e.g. cognitive therapy and medication)
for individual clusters, and for the development and reliability
testing of outcome measures – which would take years. Attempting
to match cluster to pathway/intervention has to be done by using
diagnosis as an intermediate step because that is where the
evidence currently exists. The problem then is that each cluster
relates to a number of guidelines and monitoring quality becomes
complicated – as trusts, and previously the Department of Health,
are finding in attempting to devise cluster pathways. General prac-
tice commissioners won’t have the time, resource or inclination to
undertake such complex monitoring – so cost will rule.
Broad diagnoses, as used by the National Institute for Health
and Clinical Excellence, have proved satisfactory for clinical
purposes and have readily available, reliable and applicable
outcome measures2 and, although diagnosis alone is not sufficient
for costing, in combination with clinical pathways3 they can be
costed and used for tariffs with a much better chance of reliability
and homogeneity. The very limited data that have been produced
so far are promising (available on request) but there needs to be
more extensive examination of data. The Department of Health
needs to take a lead because trusts are not going to re-analyse their
data using diagnosis and allocation to pathways unless the
Department of Health asks them to do so.
As MacDonald & Elphick1 describe, outcome measurement is
needed in any system and clustering has been very effective at
promoting use of HoNOS. However, combining diagnosis and
pathways could provide a simpler, practical approach to gathering
data for costing and tracking change than can making use of clusters.
It would also lead to an improved quality of care by linking cost
directly to the use of evidence-based guidelines and care pathways
by empowered patients, carers, providers and commissioners.
1 MacDonald AJD, Elphick M. Combining routine outcomes measurement and
Payment by Results: will it work and is it worth it? Br J Psychiatry 2011; 199:
178–9.
2 NHS South Central. Emotional Wellbeing. NHS South Central, 2011 (http://
www.sha.nhsdigital.org.uk/index.php?option=com_content&view=article&
id=52&Itemid=33).
3 NHS South Central. What services can I expect? NHS South Central, 2011
(http://www.sha.nhsdigital.org.uk/index.php?option=com_content&view=
article&id=203&Itemid=31).
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Authors’ reply: We are delighted that these responses to our
editorial expand on issues that we could not explore more fully.
Tulloch gives a cogent account of the typical methodology – not
now being followed in England – for deriving case-mix groupings
and finds the present plan wanting. He suggests a slow, careful
change to commissioning based on activity and case-mix.
Kingdon et al make the case for a system in which both diagnosis
and care pathways are central in costing and thus purchasing, only
en passant asking the crucial question of how (not whether) cost
can be firmly linked to the quality of services delivered.
Both letters focus on which type of data should be chosen. The
intended benefit of case-mix systems is to improve the direction of
resources towards the greatest local need. If that were the only
eventual use of the data items under discussion then mental health
units should collect whichever (activity counts, clusters, diagnoses,
pathways, etc.) best satisfy criteria such as Fetter’s, as Tulloch
implies. But data, once collected, have many other uses and
misuses.
Kingdon et al argue on theoretical grounds that diagnostic
categories should be better indicators than clusters of the type
and quantity of care that is required by patients. Yet as Tulloch
points out, findings from international analysis of variance studies
of actual resource consumption within diagnostic groupings have
tended to lead to their abandonment. We can add that similar
methodology was used in mental health services in England from
the early 1990s by the National Health Service Information
Authority, testing both diagnostic and multidomain descriptors
of patients’ problems, in national and multi-site trial data-sets.1
Diagnostically defined healthcare resource groups were abandoned
by the Department of Health, not only because of the modest
reduction in variance achieved, but also because of resistance by
non-psychiatrists to the collection of diagnostic data. There was
also resistance to informatics in general by a substantial
proportion of clinicians, including senior Royal College of
Psychiatrists’ leaders at the time, although that is no longer the
case.2 Clusters were seen by policy makers as more likely to be
acceptable. The fact that they become mandatory on 31 December
2011 with only this discussion in the Journal suggests that this
approach is working.
As Kingdon et al point out, diagnostic categories enable us to
use therapeutic research findings to decide which type of drug or
psychosocial approach is chosen, but that does not much affect
overall costs, and people often retain the same diagnosis
throughout many life changes. By contrast, multidomain scores
include more factors that indicate whether someone currently
needs admission or frequent contact with paid professionals,
which are the main financial determinants. And since the mental
health clustering tool (MHCT) includes symptomatology ratings,
and separates clusters into broad diagnostic groups anyway, the
statistical benefits of diagnosis have not been entirely lost. Until
there is more empirical evidence from costing studies, the relative
merits of diagnostic versus multidomain data will remain
debatable. Of course their value in outcomes and other quality
monitoring, and predicting prognosis, must also be considered
in developing mental health informatics generally. Prognosis is
important because there is more ’value’ in resolving a situation
that would otherwise become chronic.
We do not support the automatic assignment of patients to
any form of treatment, pathway or package of care on the basis
of MHCT scores alone. The data may raise retrospective questions
about clinical judgements, but should not replace them.
So what should we be doing about commissioning? Tulloch
suggests in effect returning to the 1993 position and starting again.
We do not think this is possible; while we looked away, boats were
burnt. Kingdon et al propose the combination of diagnoses with
pathway data for costing purposes, but do not say quite how.
The strong argument against using intervention counts, pathway
data or other activity measures on their own for remuneration
is that there is no safeguard against unnecessary, ineffective or
inefficient interventions or pathways. Tariff ‘matrices’ in which
prices are applied to cells containing both broad diagnoses and
clinical management data have been proposed in the past,1 but
as we said above, they were abandoned. The large number of
resulting categories should theoretically reduce costing variance,
but it may be that commissioners would not in practice be able
to use them effectively.
Yeomans concentrates on Routine Clinical Outcomes
Measurement (RCOM), arguing strongly for its development
and enhancement, while wisely refraining from almost suggesting
‘Payment by Outcomes’, which would violate Goodhart’s law,
succinctly put by Strathern: ‘When a measure becomes a target,
it ceases to be a good measure’.3 We agree with nearly all his
points, especially on the importance of feedback, which are,
notwithstanding the dated survey he quotes, already coming to
pass in some parts of England, as are developments in Patient-
Reported Outcomes Measures (PROMs). Efforts to usefully
involve HoNOS in clinical work itself are being reported, although
from the other end of the earth.4 As he says, HoNOS are a start
but not the last word in outcomes measures, and we would
caution against using them for thresholds for referral or discharge.
Validity in groups is no guarantee of validity in individual cases.
With exceptions, we have been slow to grasp the twin nettles
of outcomes and costing of services, and if we are to regain the
initiative, we have to think widely and deeply about what systems
we think will work best for service users, even while change in
these very systems is accelerating. A start would be made when
trusts have clinical, outcomes, intervention, costing, human
resource and finance data on the same spreadsheets for
themselves.
Declaration of interest
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Groupings. NHS Information Authority, 2003.
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Dissociation: a valid concept?
I was saddened by Harold Merskey’s review of the second edition
of Attachment, Trauma and Multiplicity: Working with Dissociative
Identity Disorder (edited by Valerie Sinason).1 My sadness was not
primarily caused by his critical assessment of some of the material
presented, but by his inference that dissociative identity disorder
and dissociative disorders in general do not exist. Anyone
unfamiliar with dissociative disorders reading his comments
would be forgiven for being persuaded of this.
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Correspondence
Dissociative disorders have been recognised in both DSM-IV
and ICD-10 for some 25 years now. Yet among psychiatrists in
particular, they continue to be denied or misdiagnosed, causing
serious re-traumatisation for a significant number of patients.
Merskey writes of the absence of ‘critical statement[s] by a
professional society’, but fails to cite the acknowledged leaders
in the field, the International Society for the Study of Trauma
and Dissociation (ISSTD; www.isst-d.org) and the European
Society for Trauma and Dissociation (ESTD; www.estd.org). The
ISSTD includes among its members a number of eminent
psychiatrists and psychologists and it has produced extensive
online guidelines on treatment. The charity First Person Plural,
in association with the ESTD and Cheshire & Wirral Partnership
NHS Foundation Trust, has produced a training and information
DVD.2
Furthermore, the National Institute for Health and Clinical
Excellence’s guidelines accept the existence of dissociative
disorders. It has not yet produced a treatment protocol for this
condition and recommends that clinicians follow the guidelines
of the best informed organisation (www.isst-d.org/education/
treatmentguidelines-index.htm).
It should be noted that many psychiatric services and
community mental health teams across the country are now
implementing treatment protocols for dissociative identity
disorder and dissociative disorders that are not only effecting
significant changes for patients but are also bringing about cost
savings for services.3
Declaration of interest
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Author’s reply: Dissociation begins with hypnotists, was
developed by Janet, promoted by Freud and ruined by the
absurdities of multiple personality disorder.1 Consider Janet2
hypnotising ‘Lucie’, an alternative personality of this patient
producing automatic writing:
Q. ‘How are you?’
A. ‘I don’t know.’
Q. ‘There must be someone there who hears me.’
A. ‘Yes.’
Q. ‘Who is it?’
A. ‘Someone other than Lucie.’
Q. ‘Ah, Indeed!’
A. ‘Another person.’
Q. ‘Would you like us to give her a name?’
A. ‘No.’
Q. ‘Yes it will be more convenient.’
A. ‘Alright, Adrienne.’
Q. ‘Very well Adrienne. Do you hear me?’
A. ‘Yes.’
In 1889 Binet observed that Janet ‘. . . himself created her by
suggestion’.3
Hacking4 showed that the first 19th-century fugue states in
young men were in French military conscripts exploiting the novel
long-distance continental railways. In older persons fugues are
only found with dementia. Experimental attempts by excellent
social psychologists over 60 years have completely failed to
replicate repression5 and dissociation. Freud’s own accounts of
his cases with alleged repression/dissociation were completely
unreliable,6 particularly as shown in the Freud–Fliess
correspondence.7 Further, Pope et al8 have shown that a
phenomenon like dissociation (i.e. losing complete trace of some
important event and then recovering it through memory) has not
been found so far in world literature preceding 1786, and by then
Mesmer was actively using hypnotic procedures. If dissociation is
a genuine human experience, it is remarkable that it was not
known before that time.
There is no case of proven ‘dissociation’ fulfilling Pope’s
criteria without organic disorder, although many cases of alleged
dissociative memory loss exist, not to mention the generally
rejected syndrome of dissociative identity disorder, of which
dissociation is the artefactual foundation no matter how much
the name or term may be changed.
1 Merskey H. The manufacture of personalities: the production of multiple
personality disorder. Br J Psychiatry 1992; 160: 327–40.
2 Janet P. L’Automatisme psychologique. Felix Alcan, 1889.
3 Binet A. Les alte´rations de la personnalite´. Felix Alcan, 1892. Reprinted as
Alterations of Personality (ed DN Robinson). Georgetown University
Publciations of America, 1977: 146.
4 Hacking I. Mad Travelers. Reflections on the Reality of Transient Mental
Illnesses. University of Virginia, 1998.
5 Holmes DS. The evidence for repression: an examination of 60 years of
research. In Repression and Dissociation. Implications for Personality Theory,
Psychopathology, and Health (ed JL Singer). University of Chicago Press,
1990: 85–102.
6 Grunbaum A. Made-to-order evidence. Unauthorized Freud: Doubters
Confront a Legend (ed FC Crews). Viking, 1998: 76–84.
7 Masson JM (trans & ed). The Complete Letters of Sigmund Freud to Wilhelm
Fliess, 1887–1904. Belknap Press, 1986.
8 Pope Jr HG, Poliakoff MB, Parker MP, Boynes M, Hudson JI. Is dissociative
amnesia a culture bound syndrome? Findings from a survey of historical
literature. Psychol Med 2007; 37: 225–33.
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Childhood sexual abuse and chronic fatigue syndrome
We have read the important article on the premorbid risk
markers for chronic fatigue syndrome in the 1958 British birth
cohort1 with a lot of interest. The authors reported that parental
physical abuse, childhood gastrointestinal symptoms and parental
reports of many colds were independently associated with self-
reported chronic fatigue syndrome (CFS), after adjusting for
psychopathology.
Notably, the authors did not comment on the fact that
parental physical abuse, but not sexual abuse, was predictive of
CFS, even though childhood sexual abuse is a well-documented
risk factor for CFS. More precisely, chronic fatigue was
significantly predicted by childhood sexual abuse in a
population-based study by Taylor & Jason.2 Also, childhood sexual
abuse and emotional abuse were most effective in discriminating
CFS cases from control individuals in two population-based
studies by Heim et al (as well as emotional neglect in one of these
studies).3,4 A possible reason for this inconsistency is the relatively
low frequency of sexual abuse in the study by Clark et al1 (6.3 %),
compared with its frequency in the others studies (426%).2–4
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Interestingly, there may be a differential clinical effect
according to the subtype of childhood trauma. In the study by
Taylor & Jason,2 a history of childhood sexual abuse emerged as
a significant predictor of post-traumatic stress disorder.
Furthermore, significant correlations between scores on a trauma
questionnaire and scores for depression, anxiety and post-
traumatic stress were observed by Heim et al.3 These correlations
remained unchanged when the analysis was restricted to the
subscales sexual abuse and emotional neglect.
Recently, our research group examined the impact of
childhood trauma in a well-described tertiary sample of patients
with CFS. In accordance with the previously mentioned
population-based studies, childhood sexual harassment was the
best predictor of psychological symptoms in CFS (unpublished
data). Taken together, these data emphasise the importance of
childhood sexual abuse as a premorbid risk marker for CFS.
1 Clark C, Goodwin L, Stansfeld SA, Hotopf M, White PD. Premorbid risk
markers for chronic fatigue syndrome in the 1958 British birth cohort.
Br J Psychiatry 2011; 199: 323–9.
2 Taylor RR, Jason LA. Chronic fatigue, abuse-related traumatization, and
psychiatric disorders in a community-based sample. Soc Sci Med 2002; 55:
247–56.
3 Heim C, Wagner D, Maloney E, Papanicolaou DA, Solomon L, Jones JF, et al.
Early adverse experience and risk for chronic fatigue syndrome: results from
a population-based study. Arch Gen Psychiatry 2006; 63: 1258–66.
4 Heim C, Nater UM, Maloney E, Boneva R, Jones JF, Reeves WC. Childhood
trauma and risk for chronic fatigue syndrome: association with
neuroendocrine dysfunction. Arch Gen Psychiatry 2009; 66: 72–80.
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Clozapine v. chlorpromazine in treatment-naive
first-episode schizophrenia
Girgis et al1 present data on the usefulness of clozapine versus
chlorpromazine in patients with first-episode schizophrenia. The
authors must be complimented for conducting a follow-up study
of the same cohort after 9 years and being able to have such a high
retention rate. Further, the study provides information with
respect to the naturalistic setting, reflecting the true clinical
situation, and the authors have taken care of possible confounders
with appropriate statistical analysis proper explanation. However,
there are certain issues with the study. First, the title of the article
is somewhat misleading because the randomisation phase of the
study was only for the initial 2 years and after that the patients
received treatment at the discretion of the clinicians. The title
would have been appropriate if the authors were describing the
outcome in terms of efficacy/effectiveness and side-effect profile
by using survival analysis focusing on either of the medications.
But actually the authors describe the effect of clozapine and
chlorpromazine for the initial 1 year and outcome at the 9-year
follow-up. Second, we need to understand that there are
controversies in relation to the definition of first-episode
psychosis and the definition used by the authors may appear to
be very broad.2 Third, the sample size in each treatment group
that remained on the same medication (clozapine (n=21) or
chlorpromazine (n=8)) at the 9-year follow-up is too small to
generalise. Hence, to conclude that there is no difference
between clozapine and chlorpromazine with respect to
effectiveness would be wrong. Fourth, the authors also conclude
that there is no difference in metabolic and other side-effects
between the two groups; besides having incomplete baseline data
for weight there is no mention of other metabolic variables such as
high-density lipoprotein, triglyceride and blood pressure. Fifth,
more than half of the study sample (55% of the chlorpromazine
group v. 73% of the clozapine group) was not on any anti-
psychotic medication at 9-year follow-up, but the authors have
not elaborated about their clinical status. Last of all, a quarter
of participants (24%) were diagnosed with schizophreniform
disorder which might have directly affected the outcome as this
group of disorders is considered to have better outcome than
schizophrenia.
1 Girgis RR, Phillips MR, Li X, Li K, Jiang H, Wu C, et al. Clozapine v.
chlorpromazine in treatment-naive, first-episode schizophrenia: 9-year
outcomes of a randomised clinical trial. Br J Psychiatry 2011; 199: 281–8.
2 Breitborde NK, Srihari VH, Woods SW. Review of the operational definition for
first-episode psychosis. Early Interv Psychiatry 2009; 3: 259–65.
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Authors’ reply: We appreciate Nebhinani & Grover’s interest in
our study1 as well as the opportunity to respond to the six
comments. First, our study was analysed using the intent-to-treat
principle. Implicit in the intent-to-treat principle is that the
outcome is not the effect of treatment per se, but rather the effect
of initial assignment irrespective of treatment(s) received.2
Second, we agree that there are controversies as to the definition
of first-episode psychosis.3 As reported by Breitborde et al,
‘duration of psychosis’ possesses the most construct validity,
followed by other criteria, such as ‘duration of antipsychotic
medication use’ and ‘first treatment contact’.3 We conservatively
identified individuals with first-episode schizophrenia using both
duration of psychosis and duration of antipsychotic medication
use as two of our criteria. Furthermore, we included a maximum
age criterion (i.e. 40 years old at the time when symptoms began)
and symptom criteria to further narrow and restrict our study
participants to those who are most likely to have first-episode
psychosis. Third, our conclusions and main outcomes used the
intent-to-treat principle and were based on the entire sample,
rather than primarily based on the 29 individuals who remained
on their originally assigned medication after 9 years. We described
characteristics of this smaller group, without an intent to
generalise, owing to the obvious lack of representativeness in this
subgroup of patients. Furthermore, it is important to note that the
generalisability of a clinical finding is determined by the
representativeness of the sample observed, rather than the sample
size observed.
Fourth, as described in the article, we did not have any missing
baseline data for weight for those participants whose weights were
included in our metabolic analyses. In addition, we disagree that
we indicated that there were no differences in side-effects between
the two groups. Rather, we descriptively reported differences in
tardive dyskinesia and agranulocytosis between the two treatment
groups. Finally, we did not claim that the metabolic findings in
this study are generalisable, but we do agree with Nebhinani &
Grover that it would have been valuable to report on additional
metabolic indices (e.g. lipids and blood pressure). Unfortunately,
these data were not available.
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Fifth, we reported the average percentages of time that
participants in each group took other antipsychotic medications
or resumed the original medication during the follow-up period,
rather than the percentages of individuals in each group on any
treatment regimen at 9-year follow-up. Therefore, the results
(55% for the chlorpromazine group and 73% for the clozapine
group) represent averages over the entire 7-year period, rather
than cross-sectional results at the 9-year follow-up time point.
The clinical status of these patients over the entire 9 years of the
study were reported in detail in the article, both in terms of
symptom measures, functional status, global clinical status,
medication status, side-effects, remission status and status in the
study (i.e. still in the study or dropped out).
Finally, we agree that individuals with schizophreniform
disorder are likely to have better outcomes than individuals with
schizophrenia, by definition. However, all diagnoses were
randomly and equally assigned to the two treatment groups.
Therefore, including this diagnosis is unlikely to have affected
the between-group outcomes of this study.
1 Girgis RR, Phillips MR, Li X, Li K, Jiang H, Wu C, et al. Clozapine v.
chlorpromazine in treatment-naive, first-episode schizophrenia: 9-year
outcomes of a randomised clinical trial. Br J Psychiatry 2011; 199: 281–8.
2 Lachin JM. Statistical considerations in the intent-to-treat principle. Control
Clin Trials 2000; 21: 167–89.
3 Breitborde NJK, Srihari VH, Woods SW. Review of the operational definition
for first-episode psychosis. Early Interv Psychiatry 2009; 3: 259–65.
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Corrections
Lay health worker led intervention for depressive and anxiety
disorders in India: impact on clinical and disability outcomes over
12 months. BJP, 199, 459–466. The following should be included
in the Results paragraph of the summary, p. 459: Suicide attempts/
plans showed a 36% reduction over 12 months (RR=0.64, 95%CI
0.42–0.98) among baseline ICD-10 cases. Strong effects were
observed on days out of work and psychological morbidity, and
modest effects on overall disability.
The online version of this paper has been corrected post-publication,
in deviation from print and in accordance with this correction.
Clozapine and bladder control (letter). BJP, 199, 518–519. The
author of this letter is: Yatan Balhara, Department of Psychiatry,
Lady Hardinge Medical College and Smt. SK Hospital, New Delhi,
India 110001. Email: ypsbalhara@gmail.com.
The online version of this letter has been corrected post-publication,
in deviation from print and in accordance with this correction.
doi: 10.1192/bjp.200.2.166
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